Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITE-ALS: Usnoflast in Amyotrophic Lateral Sclerosis
NCT07023835Phase 2Recruiting
- Sponsor
- Zydus Therapeutics
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of usnoflast in amyotrophic lateral sclerosis (ALS), sponsored by Zydus Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
usnoflast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07023835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023835.